Cargando…

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy

Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage. Recent active structures of the calcitonin (CT) and glucagon-like peptide-1 (GLP-1) receptors reveal dist...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Maso, Emma, Zhu, Yue, Pham, Vi, Reynolds, Christopher A., Deganutti, Giuseppe, Hick, Caroline A., Yang, Dehua, Christopoulos, Arthur, Hay, Debbie L., Wang, Ming-Wei, Sexton, Patrick M., Furness, Sebastian G.B., Wootten, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908784/
https://www.ncbi.nlm.nih.gov/pubmed/29454620
http://dx.doi.org/10.1016/j.bcp.2018.02.005
_version_ 1783315761646796800
author Dal Maso, Emma
Zhu, Yue
Pham, Vi
Reynolds, Christopher A.
Deganutti, Giuseppe
Hick, Caroline A.
Yang, Dehua
Christopoulos, Arthur
Hay, Debbie L.
Wang, Ming-Wei
Sexton, Patrick M.
Furness, Sebastian G.B.
Wootten, Denise
author_facet Dal Maso, Emma
Zhu, Yue
Pham, Vi
Reynolds, Christopher A.
Deganutti, Giuseppe
Hick, Caroline A.
Yang, Dehua
Christopoulos, Arthur
Hay, Debbie L.
Wang, Ming-Wei
Sexton, Patrick M.
Furness, Sebastian G.B.
Wootten, Denise
author_sort Dal Maso, Emma
collection PubMed
description Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage. Recent active structures of the calcitonin (CT) and glucagon-like peptide-1 (GLP-1) receptors reveal distinct engagement of peptides with extracellular loops (ECLs) 2 and 3, and mutagenesis of the GLP-1R has implicated these loops in dynamics of receptor activation. In the current study, we have mutated ECLs 2 and 3 of the human CT receptor (CTR), to interrogate receptor expression, peptide affinity and efficacy. Integration of these data with insights from the CTR and GLP-1R active structures, revealed marked diversity in mechanisms of peptide engagement and receptor activation between the CTR and GLP-1R. While the CTR ECL2 played a key role in conformational propagation linked to Gs/cAMP signalling this was mechanistically distinct from that of GLP-1R ECL2. Moreover, ECL3 was a hotspot for distinct ligand- and pathway-specific effects, and this has implications for the future design of biased agonists of class B GPCRs.
format Online
Article
Text
id pubmed-5908784
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-59087842018-04-23 Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy Dal Maso, Emma Zhu, Yue Pham, Vi Reynolds, Christopher A. Deganutti, Giuseppe Hick, Caroline A. Yang, Dehua Christopoulos, Arthur Hay, Debbie L. Wang, Ming-Wei Sexton, Patrick M. Furness, Sebastian G.B. Wootten, Denise Biochem Pharmacol Article Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage. Recent active structures of the calcitonin (CT) and glucagon-like peptide-1 (GLP-1) receptors reveal distinct engagement of peptides with extracellular loops (ECLs) 2 and 3, and mutagenesis of the GLP-1R has implicated these loops in dynamics of receptor activation. In the current study, we have mutated ECLs 2 and 3 of the human CT receptor (CTR), to interrogate receptor expression, peptide affinity and efficacy. Integration of these data with insights from the CTR and GLP-1R active structures, revealed marked diversity in mechanisms of peptide engagement and receptor activation between the CTR and GLP-1R. While the CTR ECL2 played a key role in conformational propagation linked to Gs/cAMP signalling this was mechanistically distinct from that of GLP-1R ECL2. Moreover, ECL3 was a hotspot for distinct ligand- and pathway-specific effects, and this has implications for the future design of biased agonists of class B GPCRs. Elsevier Science 2018-04 /pmc/articles/PMC5908784/ /pubmed/29454620 http://dx.doi.org/10.1016/j.bcp.2018.02.005 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dal Maso, Emma
Zhu, Yue
Pham, Vi
Reynolds, Christopher A.
Deganutti, Giuseppe
Hick, Caroline A.
Yang, Dehua
Christopoulos, Arthur
Hay, Debbie L.
Wang, Ming-Wei
Sexton, Patrick M.
Furness, Sebastian G.B.
Wootten, Denise
Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
title Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
title_full Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
title_fullStr Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
title_full_unstemmed Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
title_short Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
title_sort extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908784/
https://www.ncbi.nlm.nih.gov/pubmed/29454620
http://dx.doi.org/10.1016/j.bcp.2018.02.005
work_keys_str_mv AT dalmasoemma extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT zhuyue extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT phamvi extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT reynoldschristophera extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT deganuttigiuseppe extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT hickcarolinea extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT yangdehua extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT christopoulosarthur extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT haydebbiel extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT wangmingwei extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT sextonpatrickm extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT furnesssebastiangb extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy
AT woottendenise extracellularloops2and3ofthecalcitoninreceptorselectivelymodifyagonistbindingandefficacy